Oric Pharmaceuticals Inc (ORIC) - Total Assets
Based on the latest financial reports, Oric Pharmaceuticals Inc (ORIC) holds total assets worth $436.76 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See ORIC equity to assets ratio to measure how much of total assets are equity-financed.
Oric Pharmaceuticals Inc - Total Assets Trend (2017–2025)
This chart illustrates how Oric Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. Explore long-term investment intensity of Oric Pharmaceuticals Inc to see how much of total assets are deployed in long-term investments.
Oric Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Oric Pharmaceuticals Inc's total assets of $436.76 Million consist of 70.2% current assets and 29.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 11.1% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Oric Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Oric Pharmaceuticals Inc worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Oric Pharmaceuticals Inc's current assets represent 70.2% of total assets in 2025, a decrease from 88.6% in 2017.
- Cash Position: Cash and equivalents constituted 11.1% of total assets in 2025, down from 86.0% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Oric Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Oric Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩18.34 Trillion |
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.82 Billion |
|
Abivax SA
PA:ABVX
|
France | €584.34 Million |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩703.48 Billion |
|
Chongqing Zhifei Bio Products
SHE:300122
|
China | CN¥29.09 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Theravance Biopharma Inc
F:0TB
|
Germany | €415.46 Million |
Oric Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 16.33 | 12.00 | 26.75 |
| Quick Ratio | 16.33 | 12.00 | 26.75 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $272.46 Million | $193.82 Million | $255.05 Million |
Oric Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Oric Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.99 |
| Latest Market Cap to Assets Ratio | 2.01 |
| Asset Growth Rate (YoY) | 49.9% |
| Total Assets | $411.00 Million |
| Market Capitalization | $828.14 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Oric Pharmaceuticals Inc's assets at a significant premium (2.01x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Oric Pharmaceuticals Inc's assets grew by 49.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Oric Pharmaceuticals Inc (2017–2025)
The table below shows the annual total assets of Oric Pharmaceuticals Inc from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $411.00 Million | +49.92% |
| 2024-12-31 | $274.14 Million | +7.64% |
| 2023-12-31 | $254.69 Million | +1.73% |
| 2022-12-31 | $250.36 Million | -16.17% |
| 2021-12-31 | $298.64 Million | -0.12% |
| 2020-12-31 | $299.00 Million | +217.77% |
| 2019-12-31 | $94.09 Million | +101.34% |
| 2018-12-31 | $46.73 Million | +55.65% |
| 2017-12-31 | $30.02 Million | -- |
About Oric Pharmaceuticals Inc
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target… Read more